Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population On Track to Initiate Phase 3 Study Calendar Q4 2021 with Data Expected Calendar 2H 2022 Jun 29, 2021, 07:30 ET CRANBURY, N.J., June 29, 2021 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN) a …